TY - JOUR T1 - An Antioxidant Enzyme Therapeutic for COVID-19 JF - bioRxiv DO - 10.1101/2020.07.15.205211 SP - 2020.07.15.205211 AU - Meng Qin AU - Zheng Cao AU - Jing Wen AU - Qingsong Yu AU - Chaoyong Liu AU - Fang Wang AU - Fengmei Yang AU - Yanyan Li AU - Gregory Fishbein AU - Sen Yan AU - Bin Xu AU - Yi Hou AU - Zhenbo Ning AU - Kaili Nie AU - Ni Jiang AU - Zhen Liu AU - Jun Wu AU - Yanting Yu AU - Heng Li AU - Huiwen Zheng AU - Jing Li AU - Weihua Jin AU - Sheng Pan AU - Shuai Wang AU - Jianfeng Chen AU - Zhihua Gan AU - Zhanlong He AU - Yunfeng Lu Y1 - 2020/01/01 UR - http://biorxiv.org/content/early/2020/07/15/2020.07.15.205211.abstract N2 - The COVID-19 pandemic has taken a significant toll on people worldwide, and there are currently no specific antivirus drugs or vaccines. We report herein a therapeutic based on catalase, an antioxidant enzyme that can effectively breakdown hydrogen peroxide and minimize the downstream reactive oxygen species, which are excessively produced resulting from the infection and inflammatory process. Catalase assists to regulate production of cytokines, protect oxidative injury, and repress replication of SARS-CoV-2, as demonstrated in human leukocytes and alveolar epithelial cells, and rhesus macaques, without noticeable toxicity. Such a therapeutic can be readily manufactured at low cost as a potential treatment for COVID-19.Competing Interest StatementPatent Applied. ER -